Grossman E, Messerli FH, Grodzicki T, Kowey P (1996). “Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?”. JAMA276 (16): 1328–31. doi:10.1001/jama.276.16.1328. PMID8861992.
King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B (2003). Flenady, Vicki. ed. “Calcium channel blockers for inhibiting preterm labour”. Cochrane database of systematic reviews (Online) (1): CD002255. doi:10.1002/14651858.CD002255. PMID12535434.
Thompson AE, Pope JE (2005). “Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis”. Rheumatology (Oxford, England)44 (2): 145–50. doi:10.1093/rheumatology/keh390. PMID15546967.
Ezri T, Susmallian S (2003). “Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure”. Dis. Colon Rectum46 (6): 805–8. doi:10.1007/s10350-004-6660-8. PMID12794583.
“Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)”. Lancet356 (9227): 366–72. (2000). doi:10.1016/S0140-6736(00)02527-7. PMID10972368.
Poole-Wilson PA, Kirwan BA, Vokó Z, de Brouwer S, van Dalen FJ, Lubsen J (2006). “Safety of nifedipine GITS in stable angina: the ACTION trial”. Cardiovas Drugs Ther20 (1): 45–54. doi:10.1007/s10557-006-6312-4. PMID16552473.
“Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms”. Journal Clinical Pharm Ther30 (2): 153–8. (2005). doi:10.1111/j.1365-2710.2004.00618.x. PMID15811168.
Luther, James M. (2014). “Is there a new dawn for selective mineralocorticoid receptor antagonism?”. Current Opinion in Nephrology and Hypertension23 (5): 456–461. doi:10.1097/MNH.0000000000000051. ISSN1062-4821.
Furberg CD, Psaty BM, Meyer JV (1995). “Nifedipine. Dose-related increase in mortality in patients with coronary heart disease”. Circulation92 (5): 1326–31. doi:10.1161/01.cir.92.5.1326. PMID7648682.
Opie LH, Messerli FH (1995). “Nifedipine and mortality. Grave defects in the dossier”. Circulation92 (5): 1068–73. doi:10.1161/01.cir.92.5.1068. PMID7648646.
Grossman E, Messerli FH, Grodzicki T, Kowey P (1996). “Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?”. JAMA276 (16): 1328–31. doi:10.1001/jama.276.16.1328. PMID8861992.
King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B (2003). Flenady, Vicki. ed. “Calcium channel blockers for inhibiting preterm labour”. Cochrane database of systematic reviews (Online) (1): CD002255. doi:10.1002/14651858.CD002255. PMID12535434.
Thompson AE, Pope JE (2005). “Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis”. Rheumatology (Oxford, England)44 (2): 145–50. doi:10.1093/rheumatology/keh390. PMID15546967.
Ezri T, Susmallian S (2003). “Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure”. Dis. Colon Rectum46 (6): 805–8. doi:10.1007/s10350-004-6660-8. PMID12794583.
“Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)”. Lancet356 (9227): 366–72. (2000). doi:10.1016/S0140-6736(00)02527-7. PMID10972368.
Poole-Wilson PA, Kirwan BA, Vokó Z, de Brouwer S, van Dalen FJ, Lubsen J (2006). “Safety of nifedipine GITS in stable angina: the ACTION trial”. Cardiovas Drugs Ther20 (1): 45–54. doi:10.1007/s10557-006-6312-4. PMID16552473.
“Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms”. Journal Clinical Pharm Ther30 (2): 153–8. (2005). doi:10.1111/j.1365-2710.2004.00618.x. PMID15811168.
“[Pharmacology of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040)]” (German). Arzneimittel-Forschung22 (1): 1–14. (1972). PMID4622472.
Furberg CD, Psaty BM, Meyer JV (1995). “Nifedipine. Dose-related increase in mortality in patients with coronary heart disease”. Circulation92 (5): 1326–31. doi:10.1161/01.cir.92.5.1326. PMID7648682.
Opie LH, Messerli FH (1995). “Nifedipine and mortality. Grave defects in the dossier”. Circulation92 (5): 1068–73. doi:10.1161/01.cir.92.5.1068. PMID7648646.
Luther, James M. (2014). “Is there a new dawn for selective mineralocorticoid receptor antagonism?”. Current Opinion in Nephrology and Hypertension23 (5): 456–461. doi:10.1097/MNH.0000000000000051. ISSN1062-4821.